The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

Ramsey LB1, Johnson SG2, Caudle KE1, Haidar CE1, Voora D3, Wilke RA4, Maxwell WD5, McLeod HL6, Krauss RM7, Roden DM8, Feng Q8, Cooper-DeHoff RM9, Gong L10, Klein TE10, Wadelius M11, Niemi M12.

Author information

Abstract

Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for simvastatin based on SLCO1B1 genotype. This article is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy.

PMID:: 24918167; [PubMed - indexed for MEDLINE]
PMCID:: PMC4169720

Free PMC Article

-.-.-

full text from ► Clinical Pharmacogenetics Implementation Consortium

National Guideline Clearinghouse | The Clinical Pharmacogenetics Implementation Consortium guideline for <em>SLCO1B1</em> and simvastatin-induced myopathy: 2014 update.

Clinical Pharmacogenetics Implementation Consortium

Guideline Title

The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

Bibliographic Source(s)

Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM, Feng Q, Cooper-DeHoff RM, Gong L, Klein TE, Wadelius M, Niemi M. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014 Oct;96(4):423-8. [37 references]PubMed External Web Site Policy

Guideline Status

This is the current release of the guideline.

This guideline updates a previous version: Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M, Clinical Pharmacogenetics Implementation Consortium (CPIC). The Clinical Pharmacogenetics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012 Jul;92(1):112-7. [41 references]

This guideline meets NGC's 2013 (revised) inclusion criteria.